The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib

Yang, Jin-Ru; Zhou, Dan-Yang; Wu, Ying; Zhu, Ying; Lin, Zhen-Yu; Zhang, Tao; Yu, Dan-Dan

doi:10.7150/jca.65339



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2022; 13(1):15-20. doi:10.7150/jca.65339 This issue Cite

Research Paper

The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib

Jin-Ru Yang^1#, Dan-Yang Zhou^1,2#, Ying Wu², Ying Zhu¹, Zhen-Yu Lin¹, Tao Zhang^1✉, Dan-Dan Yu^1✉

1. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China;
2. Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Rd, Guangzhou, 510060, China.
# These authors contributed equally to this article.

Citation:

Yang JR, Zhou DY, Wu Y, Zhu Y, Lin ZY, Zhang T, Yu DD. The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib. J Cancer 2022; 13(1):15-20. doi:10.7150/jca.65339. https://www.jcancer.org/v13p0015.htm

Other styles

Abstract

Background: There is strong evidence that apatinib is effective in the treatment of third- or later-line advanced metastatic gastric cancer (mGC). Hematology prediction index is a convenient and cheap method to predict the prognosis of disease. However, the prognosis of baseline hematological parameters of peripheral blood, such as neutrophil-to-lymphocyte ratio (NLR), carbohydrate antigen 125 (CA125) and albumin (ALB) on mGC treated with apatinib have not been identified.

Methods: We retrospectively analyzed mGC received apatinib between 1 January 2014 and 30 June 2021. Survival analyses were performed using the Kaplan-Meier method and Cox-proportional hazards model.

Results: A total of 117 patients were included in this study. The cutoff value of NLR, CA125 and ALB was 2.25, 19.24 U/ml and 37.60 g/L, respectively. The disease control rates (DCR) in the high and low NLR groups were 52.94% and 73.47% (P=0.024); 48.28% and 74.58% (P=0.003) in high and low CA125 groups; 72.97% and 41.86% (P=0.001) in high and low ALB groups. By survival analysis, increasing NLR (P=0.003), CA125 (P<0.001) and decreasing ALB (P<0.001) predicted a shorter PFS after apatinib. NLR (P=0.015), CA125 (P=0.004) and ALB (P=0.005) were significantly predictors for PFS in mGC treated with aptinib.

Conclusion: Increasing NLR, CA125 and decreasing ALB were associated with poorer clinical efficiency and prognosis after apatinib treatment.

Keywords: Neutrophil-to-lymphocyte ratio, CA125, albumin, apatinib, metastatic gastric cancer

Citation styles

APA

Yang, J.R., Zhou, D.Y., Wu, Y., Zhu, Y., Lin, Z.Y., Zhang, T., Yu, D.D. (2022). The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib. Journal of Cancer, 13(1), 15-20. https://doi.org/10.7150/jca.65339.

ACS

Yang, J.R.; Zhou, D.Y.; Wu, Y.; Zhu, Y.; Lin, Z.Y.; Zhang, T.; Yu, D.D. The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib. J. Cancer 2022, 13 (1), 15-20. DOI: 10.7150/jca.65339.

NLM

CSE

Yang JR, Zhou DY, Wu Y, Zhu Y, Lin ZY, Zhang T, Yu DD. 2022. The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib. J Cancer. 13(1):15-20.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.